Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The UBE2C/CDH1/DEPTOR axis is an oncogene and tumor suppressor cascade in lung cancer cells
Shizhen Zhang, … , Xiufang Xiong, Yi Sun
Shizhen Zhang, … , Xiufang Xiong, Yi Sun
Published December 22, 2022
Citation Information: J Clin Invest. 2023;133(4):e162434. https://doi.org/10.1172/JCI162434.
View: Text | PDF
Research Article Cell biology Oncology Article has an altmetric score of 1

The UBE2C/CDH1/DEPTOR axis is an oncogene and tumor suppressor cascade in lung cancer cells

  • Text
  • PDF
Abstract

Ubiquitin-conjugating enzyme E2C (UBE2C) mediates ubiquitylation chain formation via the K11 linkage. While previous in vitro studies showed that UBE2C plays a growth-promoting role in cancer cell lines, the underlying mechanism remains elusive. Still unknown is whether and how UBE2C plays a promoting role in vivo. Here we report that UBE2C was indeed essential for growth and survival of lung cancer cells harboring Kras mutations, and UBE2C was required for KrasG12D-induced lung tumorigenesis, since Ube2c deletion significantly inhibited tumor formation and extended the lifespan of mice. Mechanistically, KrasG12D induced expression of UBE2C, which coupled with APC/CCDH1 E3 ligase to promote ubiquitylation and degradation of DEPTOR, leading to activation of mTORC signaling. Importantly, DEPTOR levels fluctuated during cell cycle progression in a manner dependent on UBE2C and CDH1, indicating their physiological connection. Finally, Deptor deletion fully rescued the tumor inhibitory effect of Ube2c deletion in the KrasG12D lung tumor model, indicating a causal role of Deptor. Taken together, our study shows that the UBE2C/CDH1/DEPTOR axis forms an oncogene and tumor suppressor cascade that regulates cell cycle progression and autophagy and validates UBE2C an attractive target for lung cancer associated with Kras mutations.

Authors

Shizhen Zhang, Xiahong You, Yawen Zheng, Yanwen Shen, Xiufang Xiong, Yi Sun

×

Figure 1

Manipulation of UBE2C, but not UBE2S, affects the proliferation and survival of lung cancer cells.

Options: View larger image (or click on image) Download as PowerPoint
Manipulation of UBE2C, but not UBE2S, affects the proliferation and surv...
(A and B) A427 (A) and H1792 (B) cells were transfected with siRNA targeting UBE2C or control (siCont) for 24 hours. Cells were then seeded in 96-well plates in triplicate and analyzed with a CCK-8 cell proliferation assay. (C and D) A427 (C) and H1792 (D) cells were transfected with siRNA targeting UBE2C, UBE2S, or siCont for 24 hours, followed by clonogenic survival assay. Representative pictures were taken (top) and colonies were counted and are shown as mean ± SEM (n = 3) (bottom). (E) MEFs were infected with Ad-GFP or Ad-Cre for 72 hours and analyzed by CCK-8 cell proliferation assay or IB (inset). (F and G) H1792 (F) and H358 (G) cells were transfected with plasmid expressing FLAG-tagged UBE2C or vector control for 48 hours and analyzed by CCK-8 cell proliferation assay or IB (inset). (H–J) A427 (H), H23 (I), and H1792 (J) cells were transfected with siRNA targeting UBE2C or siCont for 48 hours, followed by FACS analysis. (K) H1792 and A427 cells were transfected with siRNA targeting UBE2C or siCont for 48 hours, followed by IB with indicated antibodies. *P < 0.05; **P < 0.01 by 2-tailed Student’s t test (A, B, and E–J) or 1-way ANOVA test (C and D).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 1 X users
7 readers on Mendeley
See more details